This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
RedHill Biopharma Ltd., a biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary, and orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers in Israel.View RDHL key stats
Redhill Biopharma Ltd - RDHL - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Redhill Biopharma Ltd as a
Hold with a ratings score of C-.
Report Snippet: We rate REDHILL BIOPHARMA LTD (RDHL) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow.